Two-year Effectiveness of Zoledronic Acid with or Without Eldecalcitol in Japanese Patients with Osteoporosis: A Randomized Prospective Study

Overview

Journal Osteoporos Sarcopenia

Date 2022 Jul 14

PMID 35832418

Authors

Takeshi Mochizuki

Koichiro Yano

Katsunori Ikari

Ken Okazaki

Affiliations

Soon will be listed here.

Abstract

Objectives: This study aims to examine the 2-year outcomes of zoledronic acid (ZOL) with or without eldecalcitol (ELD) on bone mineral density (BMD) and fracture in Japanese patients with osteoporosis.

Methods: The subjects were 98 patients who were randomly (1:1) assigned to treatment with ZOL combined with ELD (ZOL + ELD group; n = 51) and ZOL alone (ZOL group; n = 47). Treatment efficacy was examined based on a comparison of changes in BMD from baseline (ΔBMD) in the lumbar spine, total hip, and femoral neck in the 2 groups.

Results: The percent change from baseline in BMD values for the lumbar spine, total hip, and femoral neck at 24 months were 10.8% ± 6.1%, 6.0% ± 6.6%, and 5.1% ± 5.1%, respectively, in the ZOL + ELD group, and 7.7% ± 6.2%, 5.1% ± 5.6%, and 2.9% ± 8.3%, respectively, in the ZOL group. The percent change from baseline BMD for the lumbar spine at 24 months differed significantly between the 2 groups.

Conclusions: The effect of a combination of ZOL + ELD on BMD for 24 months was more favorable than that of ZOL alone. This drug combination is promising for the treatment of drug-naïve Japanese patients with primary osteoporosis.

Citing Articles

Osteoporosis management-current and future perspectives - A systemic review.

Anish R, Nair A J Orthop. 2024; 53:101-113.

PMID: 38495575 PMC: 10940894. DOI: 10.1016/j.jor.2024.03.002.

Significant change for body composition data.

Lee J, Alghamry A Osteoporos Sarcopenia. 2022; 8(3):131.

PMID: 36268495 PMC: 9577187. DOI: 10.1016/j.afos.2022.09.005.

References

Cauley J, Thompson D, Ensrud K, Scott J, Black D . Risk of mortality following clinical fractures. Osteoporos Int. 2000; 11(7):556-61. DOI: 10.1007/s001980070075. View

Jiang Y, Tang H, Ma X, Cheng Q, Lin H, Jin X . Eldecalcitol increases bone mineral density in Chinese osteoporotic patients without vitamin D or calcium supplementation. J Bone Miner Metab. 2019; 37(6):1036-1047. DOI: 10.1007/s00774-019-01009-9. View

Nishimura A, Akeda K, Kato K, Asanuma K, Yamada T, Uchida A . Osteoporosis, vertebral fractures and mortality in a Japanese rural community. Mod Rheumatol. 2013; 24(5):840-3. DOI: 10.3109/14397595.2013.866921. View

Nakamura T, Fukunaga M, Nakano T, Kishimoto H, Ito M, Hagino H . Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study). Osteoporos Int. 2016; 28(1):389-398. PMC: 5206287. DOI: 10.1007/s00198-016-3736-y. View

Matsumoto T, Kubodera N . ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects. J Steroid Biochem Mol Biol. 2007; 103(3-5):584-6. DOI: 10.1016/j.jsbmb.2006.12.088. View

Takeuchi Y, Hashimoto J, Kakihata H, Nishida Y, Kumagai M, Yamagiwa C . Effectiveness of monthly intravenous ibandronate injections in a real-world setting: Subgroup analysis of a postmarketing observational study. Osteoporos Sarcopenia. 2019; 5(1):11-18. PMC: 6452926. DOI: 10.1016/j.afos.2019.02.002. View

Harada S, Mizoguchi T, Kobayashi Y, Nakamichi Y, Takeda S, Sakai S . Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J Bone Miner Res. 2011; 27(2):461-73. DOI: 10.1002/jbmr.555. View

Greenspan S, Perera S, Ferchak M, Nace D, Resnick N . Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA Intern Med. 2015; 175(6):913-21. PMC: 4843134. DOI: 10.1001/jamainternmed.2015.0747. View

Melton 3rd L, Therneau T, Larson D . Long-term trends in hip fracture prevalence: the influence of hip fracture incidence and survival. Osteoporos Int. 1998; 8(1):68-74. DOI: 10.1007/s001980050050. View

10.

Forsen L, Sogaard A, Meyer H, Edna T, Kopjar B . Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int. 1999; 10(1):73-8. DOI: 10.1007/s001980050197. View

11.

Shiraki M, Saito H, Matsumoto T . Eldecalcitol normalizes bone turnover markers regardless of their pre-treatment levels. Curr Med Res Opin. 2012; 28(9):1547-52. DOI: 10.1185/03007995.2012.712506. View

12.

Matsumoto T, Takano T, Yamakido S, Takahashi F, Tsuji N . Comparison of the effects of eldecalcitol and alfacalcidol on bone and calcium metabolism. J Steroid Biochem Mol Biol. 2010; 121(1-2):261-4. DOI: 10.1016/j.jsbmb.2010.03.035. View

13.

Cooper C, Atkinson E, Jacobsen S, OFallon W, Melton 3rd L . Population-based study of survival after osteoporotic fractures. Am J Epidemiol. 1993; 137(9):1001-5. DOI: 10.1093/oxfordjournals.aje.a116756. View

14.

Tan W, Sun J, Zhou L, Li Y, Wu X . Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis. J Clin Pharm Ther. 2016; 41(5):519-23. DOI: 10.1111/jcpt.12429. View

15.

Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-22. DOI: 10.1056/NEJMoa067312. View

16.

Kikuta J, Kawamura S, Okiji F, Shirazaki M, Sakai S, Saito H . Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D. Proc Natl Acad Sci U S A. 2013; 110(17):7009-13. PMC: 3637769. DOI: 10.1073/pnas.1218799110. View

17.

Saito H, Kakihata H, Nishida Y, Yatomi S, Nihojima S, Kobayashi Y . The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese patients with osteoporosis: interim report. J Bone Miner Metab. 2016; 35(4):456-463. DOI: 10.1007/s00774-016-0779-2. View

18.

Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T . A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study. Bone. 2011; 49(4):605-12. DOI: 10.1016/j.bone.2011.07.011. View

19.

Matsumoto T, Miki T, Hagino H, Sugimoto T, Okamoto S, Hirota T . A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2005; 90(9):5031-6. DOI: 10.1210/jc.2004-2552. View

20.

Shiraki M, Kuroda T, Takeuchi Y, Sugimoto T, Tanaka S, Suzuki H . Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study. Calcif Tissue Int. 2021; 109(6):666-674. PMC: 8531063. DOI: 10.1007/s00223-021-00884-7. View